Aerie pharmaceuticals, inc. (AERI)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Total revenues, net

69,888

24,181

0

0

-

-

-

-

-

Costs and expenses:
Cost of goods sold

4,833

641

0

0

-

-

-

-

-

Costs and expenses:
Selling, general and administrative

138,402

120,614

56,905

34,706

30,635

20,103

10,287

5,020

3,521

Pre-approval commercial manufacturing

22,767

26,545

16,710

9,772

-

-

-

-

-

Research and development

91,378

86,123

72,078

52,394

44,451

29,869

11,883

9,273

10,695

Total costs and expenses

257,380

233,923

145,693

96,872

75,086

-

-

-

-

Loss from operations

-187,492

-209,742

-145,693

-96,872

-75,086

-49,972

-22,170

-14,293

-14,216

Other (expense) income, net

-12,179

-22,824

-1,170

-1,994

862

1,839

-8,978

-685

1,249

Loss before income taxes

-199,671

-232,566

-146,863

-98,866

-74,224

-48,133

-31,148

-

-

Income tax (benefit) expense

-90

3

-1,758

193

139

0

0

-

-

Net loss

-199,581

-232,569

-145,105

-99,059

-74,363

-48,133

-31,148

-14,978

-12,967

Net loss attributable to common stockholdersbasic and diluted

-

-

-

-

-

-48,133

-31,598

-15,643

-13,419

Net loss per common share—basic and diluted (in dollars per share)

-4.39

-5.58

-4.11

-3.40

-2.88

-2.00

-6.38

-16.39

-14.50

Weighted average number of common shares outstanding—basic and diluted (in shares)

45,427

41,663

35,324

29,135

25,781

24,086

4,955

954

925

Net loss

-199,581

-232,569

-145,105

-99,059

-74,363

-48,133

-31,148

-14,978

-12,967

Unrealized (loss) gain on available-for-sale investments

-92

28

40

111

-72

-107

0

0

-

Comprehensive loss

-199,673

-232,541

-145,065

-98,948

-74,435

-48,240

-31,148

-14,978

-12,967

Product revenues, net
Total revenues, net

69,888

24,181

0

0

-

-

-

-

-